Background/aim: Meckel's diverticulum carcinoma (MDCa) is extremely rare. It is often advanced when found, and the prognosis is poor. Effective treatment for this cancer has not yet been developed. We previously established a patient-derived xenograft (PDX) nude-mouse model of MDCa. In the present study, we investigated the efficacy of oxaliplatinum (L-OHP) and 5-fluorouracil (5-FU) on an MDCa PDX nude-mouse model.
Materials and methods: PDX mouse models of MDCa were divided into three groups (five mice per group): untreated control; L-OHP-treated; and 5-FU-treated. Tumor volumes of the three groups were compared after 2 weeks.
Results: L-OHP arrested tumor growth (p=0.038) and 5-FU apparently eradicated the tumor (p=0.007).
Conclusion: L-OHP and 5-FU are candidates for clinical first-line therapy of MDCa.
Keywords: 5-fluorouracil; Meckel’s diverticulum carcinoma; efficacy; mouse model; oxaliplatinum; patient-derived xenograft; rare cancer.
Copyright © 2023, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.